Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 62.9% in May

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 9,600 shares, a drop of 62.9% from the April 30th total of 25,900 shares. Based on an average daily volume of 310,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Astellas Pharma Price Performance

Astellas Pharma stock opened at $9.70 on Friday. The firm has a market cap of $17.55 billion, a PE ratio of -44.09 and a beta of 0.27. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80. The stock’s fifty day moving average price is $9.53 and its two-hundred day moving average price is $9.75. Astellas Pharma has a one year low of $8.37 and a one year high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.12. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. The company had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.02 billion. As a group, research analysts expect that Astellas Pharma will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.